Interestingly, a patient-derived xenograft tumor model treated with Rspo1-conjugated doxorubicin liposomes targeting Lgr5+ CSCs showed significant tumor tissue necrosis and growth inhibition.[66] This drug delivery system using liposomes conjugated with the LGR5 ligand, which may reach more CSCs and deliver drugs efficiently, could provide an effective new strategy to treat cancer. Here, RSPO1 is linked to neoplasm.